Hikma stock gains 4.71 percent as CFO change nears

Hikma stock was trading at EUR 0.89 at Lang & Schwarz on September 30, 2026 at 12:00 p.m. CEST, up 4.71 percent versus the prior close of EUR 0.85. The move came as the pharmaceutical group entered a leadership transition after a strong first half.

Hikma appointed Rebecca Hall as chief financial officer and executive director on September 24, 2026. According to Hikma, Hall will join in Q1 2027 and replace Khalid Nabilsi on the board, while Nabilsi remains deputy CEO for North America and Europe.

Branded revenue grows 15.00 percent

For the six months ended June 30, 2026, Hikma's Branded segment increased revenue by 15.00 percent. The company also said it had reiterated full-year 2026 guidance, with management pointing to continued investment in research and development, commercial capabilities and manufacturing.

Hikma's H1 performance was differentiated by segment: the Branded business supplied the clearest growth figure, while the company described its Injectables business as stabilizing. That mix matters because the group is directing more investment toward complex products and pipeline development.

Jefferies keeps a GBp 2,025 target

Jefferies reiterated a Buy rating and a GBp 2,025 price target in a report dated September 25, 2026, according to MarketBeat. The same source records Citigroup raising its target from GBp 1,700 to GBp 1,870 on August 12, 2026, while Deutsche Bank kept a GBp 1,950 target.

The analyst backdrop therefore combines a current GBp 2,025 target with a sequence of earlier upward revisions. The key operating question is whether Branded growth and the investment program can offset the execution demands in Injectables.

Hikma stock trades higher in London

On the LSE, Hikma was trading at GBp 1,628 at 11:00 a.m. London time on September 30, 2026. Market capitalization stood at GBP 3.4 billion on the same date, while the Lang & Schwarz quote was EUR 0.89, plus 4.71 percent versus EUR 0.85.